Feature | R160W | p | 95% CI | OR | |
---|---|---|---|---|---|
first-degree relatives affected with | carriers (+)n = 85 | non-carriers (-)n = 373 | Â | Â | Â |
melanoma3 | 4 (4.7%)1 | 17 (4.5%)2 | n.s. | - | - |
breast cancer4 | 4 (4.7%) | 25 (6.7%) | n.s. | - | - |
R151C | |||||
 | carriers (+)n = 74 | non-carriers (-)n = 401 |  |  |  |
melanoma | 7 (9.5%) | 11 (2.7%) | 0.0097 | 1.276–9.061 | 3.4 |
breast cancer | 5 (6.7%) | 25 (6.2%) | n.s. | - | - |
V60L | |||||
 | carriers (+) | non-carriers (-) |  |  |  |
 | n = 78 | n = 354 |  |  |  |
melanoma | 5 (6.4%) | 10 (2.8%) | n.s. | - | 2.4 |
breast cancer | 5 (6.4%) | 24 (6.7%) | n.s. | - | - |
R163Q | |||||
 | carriers (+)n = 30 | non-carriers (-)n = 354 |  |  |  |
melanoma | 1 (3.3%) | 13 (3.6%) | n.s | - | - |
breast cancer | 2 (5%) | 17 (4.8%) | n.s | - | - |
 | any of four variants positive | none of four variants positive |  |  |  |
 | carriers (+) | non-carriers (-) |  |  |  |
 | n = 245 | n = 149 |  |  |  |
melanoma | 17 (6.9%) | 3 (2.0%) | 0.03 | 1.05–12.60 | 3.6 |
breast cancer | 16 (6.5%) | 8 (5.4%) | n.s | - | - |